InterventionsHumans171,917 participants3.0 yearsCohort study

The effect of SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors on stroke risk in type 2 diabetes: a nationwide longitudinal cohort study in Sweden with contextualisation analysis

Figure 1 from EClinicalMedicine — Figure 1Mavridis et al.

EClinicalMedicine

The paper

Anastasios Mavridis, Tamar Abzhandadze, Dongni Buvarp,

Koen Simons, Björn Eliasson, Mia von Euler, Adam Viktorisson,

Katharina Stibrant Sunnerhagen

EClinicalMedicine · 23 Sep 2026

doi.org/10.1016/j.eclinm.2026.104220 PubMed 42831062

SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes & Vascular Disease Research · 4 Oct 2026
GLP-1 agonists linked to lower dementia risk after COVID-19
Drug Design, Development and Therapy · 5 Oct 2026
GLP-1 receptor agonists link to lower stroke and Alzheimer risk
Neurology Genetics · 4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Journal of the American Society of Nephrology · 4 Oct 2026